EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans

Łukasz Uram iD, Natalia Pieńkowska, Maria Misiorek, Żaneta Szymaszek, Magdalena Twardowska, Michał Siorek, Stanisław Wołowiec iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25063226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Łukasz Uram und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Glioblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme therapy remains a significant challenge since there is a lack of effective treatment for this cancer. As most of the examined gliomas express or overexpress cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptors γ (PPARγ), we decided to use these proteins as therapeutic targets. Toxicity, antiproliferative, proapoptotic, and antimigratory activity of COX-2 inhibitor (celecoxib—CXB) and/or PPARγ agonist (Fmoc-L-Leucine—FL) was examined in vitro on temozolomide resistant U-118 MG glioma cell line and comparatively on BJ normal fibroblasts and immortalized HaCaT keratinocytes. The in vivo activity of both agents was studied on C. elegans nematode. Both drugs effectively destroyed U-118 MG glioma cells via antiproliferative, pro-apoptotic, and anti-migratory effects in a concentration range 50–100 µM. The mechanism of action of CXB and FL against glioma was COX-2 and PPARγ dependent and resulted in up-regulation of these factors. Unlike reports by other authors, we did not observe the expected synergistic or additive effect of both drugs. Comparative studies on normal BJ fibroblast cells and immortalized HaCaT keratinocytes showed that the tested drugs did not have a selective effect on glioma cells and their mechanism of action differs significantly from that observed in the case of glioma. HaCaTs did not react with concomitant changes in the expression of COX-2 and PPARγ and were resistant to FL. Safety tests of repurposing drugs used in cancer therapy tested on C. elegans nematode indicated that CXB, FL, or their mixture at a concentration of up to 100 µM had no significant effect on the entire nematode organism up to 4th day of incubation. After a 7-day treatment, CXB significantly shortened the lifespan of C. elegans at 25–400 µM concentration and body length at 50–400 µM concentration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caenorhabditis elegansGlioblastomaAnimalsHumansCelecoxibTemozolomideCyclooxygenase 2PPAR gammaSulfonamidesPyrazolesApoptosisCyclooxygenase 2 InhibitorsCell LineCell Line, TumorLeucine

Stichwörter der Autor:innen

ATP levelC. elegansFmoc-L-LeucineHaCaT immortalized cellsapoptosiscelecoxibglioma U-118 MGmigrationnormal human fibroblasts BJtoxicity

Substanzen

CelecoxibTemozolomideCyclooxygenase 2(N-(9-fluorenylmethoxycarbonyl)-)-L-leucinePPAR gammaSulfonamidesPyrazolesCyclooxygenase 2 InhibitorsLeucine

Autor:innen und Institutionen

  • Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
  • Department of Experimental and Clinical Pharmacology, University of Rzeszów, Kopisto 2a, 35-959 Rzeszów, Poland.
  • Medical College, University of Rzeszów, 1a Warzywna Street, 35-310 Rzeszów, Poland.

ORCID-Profile: Łukasz Uram, Stanisław Wołowiec

Förderung

  • National Science Centre, Poland

Zitieren

APA

Uram, Ł., Pieńkowska, N., Misiorek, M., Szymaszek, Ż., Twardowska, M., Siorek, M., & Wołowiec, S. (2024). Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063226

Vancouver

Uram Ł, Pieńkowska N, Misiorek M, Szymaszek Ż, Twardowska M, Siorek M, et al. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063226

BibTeX
@article{Uram2024,
  author = {Uram, Łukasz and Pieńkowska, Natalia and Misiorek, Maria and Szymaszek, Żaneta and Twardowska, Magdalena and Siorek, Michał and Wołowiec, Stanisław},
  title = {Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25063226}
}
Kostenlos starten →